

# CBER BEST Initiative Seminar Series



**Date:**

December 6, 2023

**Time:**

11:00 -12:00 PM EDT

**Topic:**

Use of Linked Databases in Pharmacoepidemiology: Considerations for Potential Selection Bias

**Background:**

The [CBER BEST Initiative](#) Seminar Series is designed to share and discuss recent research of relevance to ongoing and future surveillance activities of CBER regulated products, namely biologics. The series focuses on safety and effectiveness of biologics including vaccines, blood components, blood-derived products, tissues and advanced therapies. The seminars will provide information on characteristics of biologics, required infrastructure, study designs, and analytic methods utilized for pharmacovigilance and pharmacoepidemiologic studies of biologics. They will also cover information regarding potential data sources, informatics challenges and requirements, utilization of real-world data and evidence, and risk-benefit analysis for biologic products. The length of each session may vary, and the presenters will be invited from outside FDA. Please see the details below for our upcoming seminar. [Anyone can register and join for free](#). Stay tuned for more details and additional webinars during the course of the year.

**Description:**

Epidemiologic studies of medications and vaccines are increasingly conducted using linked healthcare databases. However, when these linked data are only available for a subset of patients, there is a strong potential for selection bias. This seminar will focus on techniques using inverse probability of selection weights (IPSW) in conjunction with inverse probability of treatment weights (IPTW) to adjust for potential selection bias when using linked subsets to conduct epidemiologic studies within healthcare databases.

**Presenters:**

Dr. Jenny Sun

Epidemiologist, Safety Surveillance Research, Pfizer



Jenny Sun is currently an Epidemiologist in Safety Surveillance Research at Pfizer, where she leads post approval safety studies that support regulatory decision making. Before joining Pfizer, Jenny was a pharmacoepidemiology trainee and researcher at Harvard University. Her research primarily focused on leveraging healthcare databases to evaluate medication use and safety in the pediatric population and advancing methods in pharmacoepidemiology.

**Registration:**

[https://northeastern.zoom.us/webinar/register/WN\\_VJg7GHqbQd6-7pRaw32H8g](https://northeastern.zoom.us/webinar/register/WN_VJg7GHqbQd6-7pRaw32H8g)